MAPT and Alzheimer disease: However, with the possible exception of PI‐2620 and PM‐PBB3, it has proven difficult for PET ligands to reliably and sensitively detect 3R or 4R tau isoforms in the context of non‐AD primary tauopathies (FTD, PSP, CBD).80, 81